CD70-targeted allogeneic CAR T-cell therapy for clear cell renal cell carcinoma

Development of universal CAR T-cells may be more affordable, more accessible, and easier to administer in less time with fewer mechanical failures than autologous CAR T-cell therapy. Some challenges persist, including patient toxicities, depletion of CAR T-cells in vivo, and an immunosuppressive tumor microenvironment.